The available intravenous iron formulations: History, efficacy, and toxicology

被引:123
作者
Auerbach, Michael [1 ,2 ]
Macdougall, Iain [3 ]
机构
[1] Auerbach Hematol & Oncol, Private Practice, 5233 King Ave 308, Rosedale, MD 21237 USA
[2] Georgetown Univ, Sch Med, Washington, DC USA
[3] Kings Coll Hosp London, Renal Unit, London, England
关键词
Intravenous iron; iron deficiency anemia; chronic kidney disease; FERRIC GLUCONATE COMPLEX; DEFICIENCY ANEMIA; HEMODIALYSIS-PATIENTS; ORAL IRON; PHYSICOCHEMICAL PROPERTIES; ADVERSE REACTIONS; PARENTERAL IRON; HEART-FAILURE; SAFETY; THERAPY;
D O I
10.1111/hdi.12560
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A number of intravenous iron formulations have been developed over the past 65 years which rely on dextran or other compounds to prevent uncontrolled release of free iron to the circulation. High molecular weight dextran was associated with a number of serious adverse reactions and was removed from markets worldwide in 2009. The preponderance of published evidence suggests that the formulations of parenteral iron currently available in the United States, including low molecular weight iron dextran, are all safe and effective and there are no major, clinically important differences among them in terms of either efficacy or safety. For patients with chemotherapy induced anemia or with anemia of end stage renal disease who are being treated with hemodialysis, it is reasonable to use any of the iron formulations, including iron sucrose and ferric gluconate, as frequent patient encounters with health caregivers are a routine part of care and the need to administer multiple low doses of IV iron is not a major disadvantage. However, a single infusion of a total iron dose is as effective and safe when giving iron preparations containing low molecular weight iron dextran, ferumoxytol, iron isomaltoside, or ferric carboxymaltose. Use of a single total dose infusion results in a decreased number of intravenous infusions with a lower cumulative risk for infusion reactions or extravasations, a reduced need for multiple office visits and repeated utilization of medical staff, and increased convenience for physicians and patients.
引用
收藏
页码:S83 / S92
页数:10
相关论文
共 55 条
[1]   A randomized trial of intravenous and oral iron in chronic kidney disease [J].
Agarwal, Rajiv ;
Kusek, John W. ;
Pappas, Maria K. .
KIDNEY INTERNATIONAL, 2015, 88 (04) :905-914
[2]   Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. [J].
Anker, Stefan D. ;
Comin Colet, Josep ;
Filippatos, Gerasimos ;
Willenheimer, Ronnie ;
Dickstein, Kenneth ;
Drexler, Helmut ;
Luescher, Thomas F. ;
Bart, Boris ;
Banasiak, Waldemar ;
Niegowska, Joanna ;
Kirwan, Bridget-Anne ;
Mori, Claudio ;
Rothe, Barbara von Eisenhart ;
Pocock, Stuart J. ;
Poole-Wilson, Philip A. ;
Ponikowski, Piotr .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (25) :2436-2448
[3]   Intravenous iron: From anathema to standard of care [J].
Auerbach, Michael ;
Coyne, Dan ;
Ballard, Harold .
AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (07) :580-588
[4]   Results of the First American Prospective Study of IV Iron in Oral Iron Intolerant Iron Deficient Gravidas [J].
Auerbach, Michael ;
Smith, Samuel ;
James, Stephanie .
BLOOD, 2016, 128 (22)
[5]   Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia [J].
Auerbach, Michael ;
Pappadakis, Jennifer A. ;
Bahrain, Huzefa ;
Auerbach, Sarah A. ;
Ballard, Harold ;
Dahl, Naomi V. .
AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (10) :860-862
[6]   Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety [J].
Auerbach, Michael ;
Ballard, Harold .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :338-347
[7]   The Safety of Intravenous Iron Preparations: Systematic Review and Meta-analysis [J].
Avni, Tomer ;
Bieber, Amir ;
Grossman, Alon ;
Green, Hefziba ;
Leibovici, Leonard ;
Gafter-Gvili, Anat .
MAYO CLINIC PROCEEDINGS, 2015, 90 (01) :12-23
[8]  
Ayub R, 2008, JCPSP-J COLL PHYSICI, V18, P424, DOI 07.2008/JCPSP.424427
[9]  
BAIRD IM, 1954, LANCET, V2, P942
[10]   Physicochemical properties of ferumoxytol, a new intravenous iron preparation [J].
Balakrishnan, V. S. ;
Rao, M. ;
Kausz, A. T. ;
Brenner, L. ;
Pereira, B. J. G. ;
Frigo, T. B. ;
Lewis, J. M. .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (06) :489-496